home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Zymeworks Inc. - Common Stock (NY:ZYME)

N/A UNCHANGED

Last Price Updated: 7:00 PM EST, Dec 15, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference

January 06, 2022

From Zymeworks Inc.

Via Business Wire

Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani

January 05, 2022

From Zymeworks Inc.

Via Business Wire

Raising Rates ↗

December 16, 2021

The Bank of England raised its interest rate to 0.25%, setting a pattern for other countries.

Via Talk Markets

To sell or not to sell? ↗

December 14, 2021

Pfizer says its covid pill is 90% effective. PFE got higher target prices from Berenburg and Mizuho

Via Talk Markets

Inflation Surge ↗

December 10, 2021

Today the market failed to brush off inflation fears as it had done later on Thursday as inflation is at a 4 decade high.

Via Talk Markets

Omicron Surge ↗

December 09, 2021

The seemingly good level of joblessness at a mere 184,000 turns out to be less wonderful than it appears, at the lowest since 1969.

Via Talk Markets

Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment

December 09, 2021

From Zymeworks Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021 ↗

December 10, 2021

Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE:

Via Benzinga

Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer

December 08, 2021

From Zymeworks Inc.

Via Business Wire

56 Biggest Movers From Yesterday ↗

December 10, 2021

Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares jumped 84% to close at $4.95 on Thursday after the company signed an exclusive summary distribution agreement...

Via Benzinga

The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom ↗

December 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...

Via Benzinga

Topics Intellectual Property Lawsuit

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Happy December ↗

December 01, 2021

Inflation levels this year will almost certainly lower growth in 2022 because of inflation this year in everything from house prices....to stock prices.

Via Talk Markets

Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms

December 01, 2021

From Zymeworks Inc.

Via Business Wire

Tuesday Markets Review ↗

November 30, 2021

The oil price did not fall as expected over the White House release of 50 mn bbls of oil.

Via Talk Markets

Tuesday Markets Coverage ↗

November 23, 2021

GE was up on hopes for cheaper oil. But most stocks were down on oil price hike fears.

Via Talk Markets

Friday Markets Coverage ↗

November 19, 2021

Today markets are suffering alongside Austria which locked down against Covid-19 again.

Via Talk Markets

Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)

November 19, 2021

From Zymeworks Inc.

Via Business Wire

Tuesday Market Overview ↗

November 16, 2021

While gold gained modestly again today, cryptocurrencies fell hard.

Via Talk Markets

Zymeworks Names Neil Josephson, M.D., Chief Medical Officer

November 09, 2021

From Zymeworks Inc.

Via Business Wire

Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)

November 09, 2021

From Zymeworks Inc.

Via Business Wire

Zymeworks to Present at Upcoming Investor Conferences

November 08, 2021

From Zymeworks Inc.

Via Business Wire

Thursday Market Overview ↗

November 04, 2021

If you are an IBM shareholder you now own something new Kyndryl.

Via Talk Markets

Zymeworks Reports 2021 Third Quarter Financial Results

November 03, 2021

From Zymeworks Inc.

Via Business Wire

No Negative Reaction ↗

October 28, 2021

Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today.

Via Talk Markets

Tuesday Market Coverage ↗

October 26, 2021

Thermo Electron fell on the publication of its social responsibility report today.

Via Talk Markets

Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers

October 26, 2021

From Zymeworks Inc.

Via Business Wire

Cyber Currency ↗

October 26, 2021

Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck.

Via Talk Markets

Thursday Market Coverage ↗

October 21, 2021

US jobless benefit applicants last week hit a pandemic low of 290,000, below the estimate of 300,000.

Via Talk Markets

Wednesday Market Coverage ↗

October 20, 2021

Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.

Via Talk Markets

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com